Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Infliximab Exposure-Response Relationship and Thresholds Associated with Endoscopic Healing in Patients With Ulcerative Colitis.

Vande Casteele N, Jeyarajah J, Jairath V, Feagan BG, Sandborn WJ.

Clin Gastroenterol Hepatol. 2018 Oct 26. pii: S1542-3565(18)31200-X. doi: 10.1016/j.cgh.2018.10.036. [Epub ahead of print]

PMID:
30613004
2.

Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis.

Papamichael K, Van Stappen T, Vande Casteele N, Gils A, Billiet T, Tops S, Claes K, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M.

Clin Gastroenterol Hepatol. 2016 Apr;14(4):543-9. doi: 10.1016/j.cgh.2015.11.014. Epub 2015 Dec 8.

PMID:
26681486
3.

Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis.

Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT.

Aliment Pharmacol Ther. 2018 Feb;47(4):478-484. doi: 10.1111/apt.14458. Epub 2017 Dec 6.

PMID:
29210094
4.

Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis.

Brandse JF, Mathôt RA, van der Kleij D, Rispens T, Ashruf Y, Jansen JM, Rietdijk S, Löwenberg M, Ponsioen CY, Singh S, van den Brink GR, D'Haens GR.

Clin Gastroenterol Hepatol. 2016 Feb;14(2):251-8.e1-2. doi: 10.1016/j.cgh.2015.10.029. Epub 2015 Nov 9.

PMID:
26545802
5.

Optimising infliximab induction dosing for patients with ulcerative colitis.

Dreesen E, Faelens R, Van Assche G, Ferrante M, Vermeire S, Gils A, Bouillon T.

Br J Clin Pharmacol. 2019 Jan 11. doi: 10.1111/bcp.13859. [Epub ahead of print]

PMID:
30634202
6.

Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study.

Adedokun OJ, Xu Z, Padgett L, Blank M, Johanns J, Griffiths A, Ford J, Zhou H, Guzzo C, Davis HM, Hyams J.

Inflamm Bowel Dis. 2013 Dec;19(13):2753-62. doi: 10.1097/01.MIB.0000435438.84365.f7.

PMID:
24193155
7.

Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.

Papamichael K, Baert F, Tops S, Assche GV, Rutgeerts P, Vermeire S, Gils A, Ferrante M.

J Crohns Colitis. 2017 Jan;11(1):53-59. doi: 10.1093/ecco-jcc/jjw122. Epub 2016 Jul 11.

PMID:
27402915
8.

Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.

Adedokun OJ, Sandborn WJ, Feagan BG, Rutgeerts P, Xu Z, Marano CW, Johanns J, Zhou H, Davis HM, Cornillie F, Reinisch W.

Gastroenterology. 2014 Dec;147(6):1296-1307.e5. doi: 10.1053/j.gastro.2014.08.035. Epub 2014 Aug 28.

9.

A review of infliximab use in ulcerative colitis.

Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB.

Clin Ther. 2008 Feb;30(2):223-30. doi: 10.1016/j.clinthera.2008.02.014. Review.

PMID:
18343261
10.

Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.

Hassan EA, Ramadan HK, Ismael AA, Mohamed KF, El-Attar MM, Alhelali I.

Saudi J Gastroenterol. 2017 Jul-Aug;23(4):238-245. doi: 10.4103/sjg.SJG_599_16.

11.

Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?

Gonczi L, Vegh Z, Golovics PA, Rutka M, Gecse KB, Bor R, Farkas K, Szamosi T, Bene L, Gasztonyi B, Kristóf T, Lakatos L, Miheller P, Palatka K, Papp M, Patai Á, Salamon Á, Tóth GT, Vincze Á, Biro E, Lovasz BD, Kurti Z, Szepes Z, Molnár T, Lakatos PL.

J Crohns Colitis. 2017 Jun 1;11(6):697-705. doi: 10.1093/ecco-jcc/jjw203.

PMID:
27838610
12.

Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis.

Kevans D, Murthy S, Mould DR, Silverberg MS.

J Crohns Colitis. 2018 May 25;12(6):662-669. doi: 10.1093/ecco-jcc/jjy028.

PMID:
29659758
13.

Ulcerative colitis endoscopic index of severity is associated with long-term prognosis in ulcerative colitis patients treated with infliximab.

Saigusa K, Matsuoka K, Sugimoto S, Arai M, Kiyohara H, Takeshita K, Mizuno S, Mori K, Nanki K, Takeshita T, Nakazato Y, Yajima T, Naganuma M, Hisamatsu T, Ogata H, Iwao Y, Kanai T.

Dig Endosc. 2016 Sep;28(6):665-70. doi: 10.1111/den.12655. Epub 2016 Apr 21.

PMID:
26997640
14.

Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab.

Turner D, Griffiths AM, Veerman G, Johanns J, Damaraju L, Blank M, Hyams J.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1460-5. doi: 10.1016/j.cgh.2013.04.049. Epub 2013 May 11.

PMID:
23672831
15.

The impact of biological interventions for ulcerative colitis on health-related quality of life.

LeBlanc K, Mosli MH, Parker CE, MacDonald JK.

Cochrane Database Syst Rev. 2015 Sep 22;(9):CD008655. doi: 10.1002/14651858.CD008655.pub3. Review.

PMID:
26393522
16.

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S.

Gastroenterology. 2015 Jun;148(7):1320-9.e3. doi: 10.1053/j.gastro.2015.02.031. Epub 2015 Feb 24.

PMID:
25724455
17.

Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.

Paul S, Del Tedesco E, Marotte H, Rinaudo-Gaujous M, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X.

Inflamm Bowel Dis. 2013 Nov;19(12):2568-76. doi: 10.1097/MIB.0b013e3182a77b41.

PMID:
24013361
18.

Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.

Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ.

Gastroenterology. 2011 Oct;141(4):1194-201. doi: 10.1053/j.gastro.2011.06.054. Epub 2011 Jun 30.

PMID:
21723220
19.

Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.

Farkas K, Rutka M, Golovics PA, Végh Z, Lovász BD, Nyári T, Gecse KB, Kolar M, Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, Malickova K, Bálint A, Nagy F, Bor R, Milassin Á, Szepes Z, Palatka K, Lakatos PL, Lukas M, Molnár T.

J Crohns Colitis. 2016 Nov;10(11):1273-1278. Epub 2016 Apr 21.

PMID:
27106537
20.

Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis.

Ungar B, Mazor Y, Weisshof R, Yanai H, Ron Y, Goren I, Waizbard A, Yavzori M, Fudim E, Picard O, Loebstein R, Kopylov U, Dotan I, Chowers Y, Eliakim R, Ben-Horin S.

Aliment Pharmacol Ther. 2016 Jun;43(12):1293-9. doi: 10.1111/apt.13631. Epub 2016 Apr 19.

Supplemental Content

Support Center